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The mechanism by which platelets regulate the func-
tion of integrin aIIbb3 (or GPIIb/IIIa), the platelet fibrin-
ogen receptor, is unknown but may involve the binding
of proteins or other factors to integrin cytoplasmic do-
mains. To identify candidate cytoplasmic domain bind-
ing proteins, we screened a human fetal liver cDNA li-
brary in the yeast two-hybrid system, using the aIIb
cytoplasmic domain as “bait,” and isolated a novel 855-
base pair clone. The open reading frame encodes a novel
191-amino acid polypeptide (termed CIB for calcium-
and integrin-binding protein) that appears to be specific
for the cytoplasmic domain of aIIb, since it does not
interact with the av, a2, a5, b1, or b3 integrin cytoplasmic
domains in the yeast two-hybrid system. This protein
has sequence homology to two known Ca21-binding reg-
ulatory proteins, calcineurin B (58% similarity) and cal-
modulin (56% similarity), and has two EF-hand motifs
corresponding to the two C-terminal Ca21 binding do-
mains of these proteins. Moreover, recombinant CIB
specifically binds 45Ca21 in blot overlay assays. Using
reverse transcriptase-polymerase chain reaction and
Western blot analysis, we detected CIB mRNA and pro-
tein (;25 kDa), respectively, in human platelets. An en-
zyme-linked immunosorbent assay performed using ei-
ther immobilized recombinant CIB or monoclonal
antibody-captured aIIbb3 indicates a specific interaction
between CIB and intact aIIbb3. These results suggest
that CIB is a candidate regulatory molecule for integrin
aIIbb3.
Integrin-mediated adherence of cells to extracellular matrix
is important for a variety of physiological processes, such as
hemostasis, angiogenesis, and cell differentiation (1). Integrin
aIIbb3, the platelet fibrinogen receptor, is specific to the
megakaryocytic lineage. In unstimulated platelets the majority
of aIIbb3 is in an inactive conformation or low affinity state and
is unable to bind soluble ligands. Platelet agonists through
their respective receptors transduce a cascade of intracellular
signals ultimately converting aIIbb3 to an active, high affinity
state, capable of binding soluble ligands. This activation proc-
ess is termed inside-out signaling (2).
The role of the aIIb and b3 cytoplasmic domains in inside-out
signaling has been indicated using mutants of aIIbb3 trans-
fected into Chinese hamster ovary cells (3). When wild type
aIIbb3 is expressed in Chinese hamster ovary cells, it is unable
to bind soluble fibrinogen. However, when an aIIbb3 construct
lacking the aIIb cytoplasmic domain is expressed, the integrin
becomes constitutively active and binds soluble fibrinogen with
high affinity (4). Moreover, deletion of the conserved GFFKR
motif of the aIIb cytoplasmic domain makes the integrin con-
stitutively active. These data suggest that the aIIb cytoplasmic
domain helps to maintain a default low affinity state of aIIbb3.
Interestingly, a naturally occurring point mutation, Ser-7523
Pro in the b3 cytoplasmic domain, disrupts inside-out signaling
(5), indicating that the b3 cytoplasmic domain is involved in
inducing or maintaining the high affinity state. Thus, inside-
out signaling probably requires both integrin cytoplasmic do-
mains. It seems likely that during platelet activation, the con-
formations of the aIIb and b3 cytoplasmic domains are altered
as a result of an interaction with cytoplasmic factors. It is
therefore of interest to identify candidate cytoplasmic factors
and determine their roles in integrin affinity modulation. In
this regard, Shattil et al. (6), using the yeast two-hybrid sys-
tem, recently identified a novel protein termed b3-endonexin,
which interacts with the cytoplasmic domain of the b3 integrin.
Fibrinogen binding to aIIbb3 causes receptor clustering,
which induces outside-in signaling, leading to cytoskeletal re-
arrangements and localization of the integrin in focal contacts.
The mechanism of integrin-mediated signaling and localization
is unclear but is believed to involve the interaction of integrin
cytoplasmic domains with specific proteins. The b cytoplasmic
domain is required for integrin localization in focal contacts,
while the a cytoplasmic domain is required for selective asso-
ciation of aIIbb3 with focal contacts (3). The aIIb and/or b3
cytoplasmic domains have been shown to interact with talin
(7), Shc, and Grb2, proteins potentially involved in these
processes (8).
We have identified a novel Ca21-binding protein that inter-
acts specifically with the integrin aIIb subunit cytoplasmic do-
main. This protein is expressed in platelets and binds to het-
erodimeric integrin aIIbb3. It has significant homology to two
well known Ca21-binding proteins, calmodulin and calcineurin
B, which are involved in regulating the activity of a variety of
proteins. Thus, our studies identify a novel candidate intracel-
lular regulatory molecule for platelet integrin aIIbb3.
EXPERIMENTAL PROCEDURES
Construction of Vectors—The cytoplasmic domains of integrin sub-
units were amplified using polymerase chain reaction (PCR)1 from
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corresponding plasmid constructs and directionally cloned into pGBT9,
a yeast expression vector (Clontech, Palo Alto, CA). DNA sequencing
(UNC-CH Automated DNA Sequencing Facility) indicated an in-frame
fusion of each cytoplasmic domain to the 39 end of the Gal4-(1–147)
DNA binding domain.
Two-hybrid Library Screening—Human cDNA libraries derived from
fetal liver in pGAD10 (Clontech) were screened in the yeast two-hybrid
system (9, 10), for aIIb cytoplasmic domain binding proteins, as de-
scribed by the manufacturer.
Expression of GST-fusion Protein—The CIB cDNA insert was sub-
cloned into pGEX 2T (Pharmacia Biotech Inc.). The in-frame fusion was
confirmed by DNA sequencing. The GST-fusion protein was purified by
glutathione-Sepharose (Pharmacia) affinity chromatography following
elution with 10 mM reduced glutathione. Recombinant CIB was re-
leased from GST by cleavage of the GST fusion protein while on the
column with 10 units of thrombin as described by the manufacturer.
45Ca21 Binding—Proteins were separated by SDS-PAGE and elec-
trophoretically transferred to a PVDFmembrane (0.2-m pore size). Blots
were overlaid with 45Ca21 (1 mCi/ml) for 10 min as described by Ma-
ruyama et al. (11) with or without excess unlabeled CaCl2 (10 mM).
RT-PCR—Total RNA was isolated using TRIZOL reagent (Life Tech-
nologies, Inc.) from washed human platelets made free of leukocytes
and other cells. The RNA was reverse-transcribed using the 1st Strand
cDNA Synthesis Kit (Boehringer Mannheim) and random primers. PCR
amplification of specific fragments was performed for 30 cycles using
specific sense (59-CGAGTTGGCGGAGCTGT-39) and antisense (59-AG-
GATGTTGTCGATGAG-39) primers to amplify a 0.5-kb fragment of
CIB, and sense (59-GGCATTCAGTCGCTGTCA-39) and antisense (59-
CTCGTTGGCTGCGTCCA-39) primers to amplify a 1.05-kb fragment
of aIIb.
Antibodies—Polyclonal antibodies were raised against an antigenic
synthetic peptide derived from the amino acid sequence (KQEILLAHR-
RFCELLPQEQR) of CIB. The antisera were analyzed by enzyme-linked
immunosorbent assay and Western blotting to determine specificity
and titer for recombinant CIB. Monoclonal antibodies against CIB were
developed by immunizing mice with GST-CIB and screening the culture
supernatants with thrombin-cleaved CIB (North Carolina State Uni-
versity Hybridoma Facility).
In Vitro Binding Assay—Microtiter wells were coated with 10 mg/ml
recombinant CIB, monoclonal antibody 10E5 (provided by Dr. Barry
Coller, Mt. Sinai Medical Center, New York), or BSA. After blocking
with 1% BSA, 5-fold diluted platelet extract in 1% Triton X-100 con-
taining 2 mM Ca21 was added to each well and incubated for 1 h. Wells
were washed four times with PBST. Wells containing immobilized CIB
and BSA were incubated with aIIbb3 complex-specific mAb 10E5,
whereas wells containing immobilized mAb 10E5 were incubated with
recombinant CIB (10 mg/ml) followed by anti-CIB antiserum. The
amount of bound aIIbb3 and recombinant CIB were determined using
anti-mouse and anti-rabbit secondary antibody conjugated with alka-
line phosphatase, respectively.
RESULTS
Isolation and Sequence Analysis of CIB cDNA—Using the
aIIb cytoplasmic domain (aIIb-cyt) as bait, we screened a
human fetal liver cDNA library constructed in plasmid
pGAD10 encoding the GAL4 activation domain. A human
fetal liver library was of special interest because the fetal
liver produces platelets, making it a likely source of relevant
platelet-related cDNA. Out of 2 3 106 total clones screened,
we isolated a single clone (clone 8). In an experiment de-
signed to eliminate false positives, plasmid DNA from clone 8
was isolated, purified, and retransformed into the yeast
SFY526 strain alone or with one of the following: (a) pGBT9,
(b) a pGBT9 hybrid with an aIIb-cyt insert, or (c) a pGBT9
hybrid with the unrelated protein, lamin C (Fig. 1). Only
transformants that received the aIIb-cyt hybrid and clone 8
were positive for b-galactosidase activity, indicating a true
positive interaction. The clone 8 cDNA was also transformed
into the yeast SFY526 strain along with plasmid pGBT9
encoding cytoplasmic domains of integrins aIIb, av, a2, a5, b1,
or b3, and b-galactosidase activity was quantified. The prod-
uct of clone 8 failed to interact with the cytoplasmic domains
of integrins av, a2, a5, b1, and b3, indicating a relatively
specific interaction with the aIIb cytoplasmic domain (Fig. 1).
Sequence analysis of this clone indicated an 855-bp insert
and an ATG sequence (bp 47–49) in a region making it the
likely translation start site (12). The open reading frame of 573
bp encodes a polypeptide of 191 amino acids with a predicted
mass of 21.7 kDa (Fig. 2A). A consensus sequence for a poly-
adenylation recognition site (AATAAA) is located 20 bp before
the 39 end. A search of GenBankTM using the cDNA sequence
revealed no significant homology to any published genes. Kyte-
Doolittle hydropathy analysis (13) of the deduced amino acid
sequence predicts that the protein is highly hydrophilic. CIB
has a large number of acidic amino acid residues with a pre-
dicted isoelectric point of 4.48 and net charge of 213. Sequence
analysis of CIB using “Prosite” revealed an N-terminal myris-
toylation site, two consensus sites for phosphorylation by pro-
tein kinase C, and five consensus sites for phosphorylation by
casein kinase II (Fig. 2A). A search of protein data banks
indicated that the deduced amino acid sequence is novel but
shares homology with calcineurin B, the regulatory subunit of
protein phosphatase 2B (28% identity, 58% similarity) and
calmodulin (27% identity, 55% similarity) (Fig. 2B). Further
sequence analysis of CIB indicated the presence of two EF-
hand motifs that correspond to the two adjacent C-terminal
Ca21 binding domains in calcineurin B and calmodulin. The
identity between EF-hand motif I of CIB and EF-hand 3 of
calcineurin B is 39% and that of EF-hand II of CIB and EF-
hand 4 of calcineurin B is 35% (Fig. 2B).
Calcium Binding to Recombinant CIB—To determine
whether Ca21 specifically bound to CIB, we performed 45Ca21
blot overlay assays. Purified bovine calmodulin was used as a
positive control. Recombinant CIB, which was purified free
from GST as described under “Experimental Procedures,” had
a mass of ;25 kDa. 45Ca21 bound to CIB and calmodulin; the
binding was abolished upon inclusion of 10 mM unlabeled Ca21,
indicating a specific interaction (Fig. 3).
Expression of CIB in Human Platelets—To address whether
CIB is expressed in human platelets and other hematopoietic
cells or cell lines, we isolated total RNA from platelets, leuko-
cytes, HEL cells, and K-562 cells. RT-PCR was performed using
CIB-specific sense and antisense primers designed to amplify a
0.5-kb segment. As a control for the quality of platelet RNA,
aIIb-specific primers, designed to amplify a 1.05-kb segment,
were used. With CIB-specific primers, we observed the ampli-
fication of a 0.5-kb band from RNA derived from platelets and
HEL cells (Fig. 4A) indicating the presence of CIB-specific
mRNA. A slightly smaller sized band was observed from leu-
FIG. 1. Specificity of interaction of the clone 8 protein with the
aIIb cytoplasmic domain. Clone 8 plasmid DNA was co-transformed
in yeast SFY526 along with empty vector, plasmid encoding the unre-
lated protein lamin C, or plasmids encoding various integrin cytoplas-
mic domains as indicated, fused with the Gal4 DNA binding domain.
The co-transformants were assayed for b-galactosidase activity in both
filter and liquid assays.
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kocytes and K-562 cells, the identity of which is not yet known.
In contrast, none of these bands were amplified in a breast
cancer cell line (T47D). Amplification of a fragment of the
expected size (;1 kb) from platelet RNA with aIIb primers
served as a positive control and demonstrates the integrity of
the platelet RNA.
We also performed Western blot analysis using two different
monoclonal anti-CIB antibodies in an attempt to detect CIB in
platelets, HEL, and K-562 cells. Both mAbs detected an ;25-
kDa band in platelet but not in HEL or K-562 cell extracts (Fig.
4B) despite the detection of CIB mRNA in HEL cells. The
slightly higher than predicted molecular mass observed on
Western blots may be due to post-translational modification of
CIB.
In Vitro Binding of CIB to Heterodimeric Integrin aIIbb3—In
vitro binding assays were used to determine whether CIB in-
teracts with the intact heterodimeric aIIbb3 integrin. In these
experiments, purified recombinant CIB was immobilized to
microtiter wells, wells were blocked with BSA, and aIIbb3 from
platelet extract was allowed to bind. The amount of integrin
bound was quantified using mAb 10E5, an integrin complex
specific antibody. Immobilized CIB bound significantly higher
levels of aIIbb3 than did immobilized BSA in the absence of CIB
(Fig. 5A). Similar results were obtained in a reverse experi-
ment in which heterodimeric integrin aIIbb3 from platelet ly-
sate was captured on immobilized mAb 10E5 (Fig. 5B). Signif-
icantly more recombinant CIB bound to wells containing
antibody-captured integrin aIIbb3 than to similarly treated
wells lacking mAb 10E5, as detected with anti-CIB antiserum.
Moreover, CIB did not bind to immobilized mAb 10E5 alone
(data not shown). These results demonstrate an in vitro inter-
action of CIB with integrin aIIbb3.
DISCUSSION
In the present study, we attempted to identify molecules that
might interact with cytoplasmic domains of aIIbb3, using the
yeast two-hybrid system (9, 10). We isolated a novel full-length
human cDNA that encodes a polypeptide with a predicted
molecular mass of 21.7 kDa, which binds to the integrin aIIb
cytoplasmic domain and is expressed in platelets. The struc-
tural properties of CIB indicate that it is a hydrophilic calcium-
binding protein, most similar to calcineurin B and calmodulin.
Calcineurin B is a small regulatory subunit (19 kDa) of phos-
FIG. 2. Sequence analysis of clone 8. A, cDNA sequence and de-
duced amino acid sequence of clone 8. A consensus sequence for a
polyadenylation recognition site (AATAAA) is underlined. The two EF-
hand motifs are boxed. Putative sites of phosphorylation by protein
kinase C are shown by shaded circles and by casein kinase II are shown
by unshaded circles. A putative myristoylation site is indicated by a
square. B, amino acid sequence alignment of CIB with calcineurin B
(CALB) and calmodulin (CAM). Identical residues are shaded. The two
EF-hand motifs of CIB are indicated by solid lines, whereas the EF-
hand motifs of CALB and CAM are indicated by broken lines.
FIG. 3. Blot overlay assay of 45Ca21 binding to CIB. Purified
calmodulin or CIB (2 mg each) was separated by SDS-PAGE and trans-
ferred to PVDF membranes, and the membranes were overlaid with
45Ca21 (1 mCi/ml) for 10 min in the absence (A) and in the presence of
10 mM unlabeled CaCl2 (B). Lane 1, molecular size markers; lane 2,
purified bovine calmodulin; lane 3, recombinant CIB.
FIG. 4. Expression of CIB in human platelets. A, RT-PCR ampli-
fication of RNA. Total RNA was isolated and cDNA was synthesized as
described under “Experimental Procedures.” Aliquots of the cDNA syn-
thesis reaction mixture of various cellular RNAs were amplified for 30
cycles. Lanes 1 and 7, platelets; lane 2, leukocytes; lane 3, HEL cells;
lane 4, T47D cells (a transformed breast epithelial cell line); lane 5,
K-562 cells. In lane 6, clone 8 cDNA was used as template (a positive
control). Lanes 1–6, CIB specific primers, 500 bp apart, were used;
whereas in lane 7, aIIb-specific primers, 1050 bp apart, were used. B,
Western blot analysis of CIB. Proteins (200 mg) from cells lysed in
Laemmli buffer were separated using SDS-PAGE, transferred to PVDF
membranes, and blotted with mAb UN2 and mAb UN7, both raised
against recombinant CIB.
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phoprotein phosphatase 2B or calcineurin, the only known
protein phosphatase that is regulated by Ca21 and calmodulin
(14). Calcineurin is a heterodimer that also consists of a large
catalytic subunit, calcineurin A. The A subunit binds calmod-
ulin, whereas the B subunit binds four atoms of Ca21 (14) and
is a member of the “EF-hand” family of Ca21-binding proteins.
Calmodulin is a well described Ca21-dependent regulatory mol-
ecule for several different enzymes. Unlike calcineurin B and
calmodulin, CIB has two rather than four EF-hand motifs.
Nonetheless, the similarity between CIB and these regulatory
molecules raises the question as to whether CIB also serves as
a regulatory subunit for an unknown enzyme(s) as well as for
integrin aIIbb3.
Because CIB appears to interact only with aIIb and not with
other integrin a subunits (av, a2, and a5) in the yeast two-
hybrid system, it is unlikely that CIB binds to the membrane-
proximal GFFKR region of the aIIb cytoplasmic domain, since
this sequence is common to all integrin a subunits. This is in
contrast to calreticulin, a Ca21-binding protein that binds to
GFFKR (15) and co-purifies with several integrins (16). This
suggests that the CIB binding site on the aIIb cytoplasmic
domain may include the highly acidic portion distal to the
membrane.
It is well documented that a rise in intracellular Ca21 is a
prerequisite for platelet activation by many agonists. How in-
tracellular calcium regulates the function of integrins is not
clearly understood. One possibility is that an increase in intra-
cellular Ca21 may regulate integrin function through CIB or a
CIB-like protein. In fact, it has been shown that neutrophil
migration on vitronectin is regulated by calcineurin; migration
is decreased by inhibitors of calcineurin or intracellular Ca21
chelators, suggesting that increases in [Ca21]i promote neutro-
phil migration and reduce integrin-mediated cell adhesion to
vitronectin (17). Interaction of fibronectin and integrin a5b1 in
vitro has also been shown to be regulated by calcineurin (18).
It was further demonstrated that Ca21 and calcineurin reg-
ulate recycling of integrin avb3 to the leading edge of migrating
neutrophils (17, 19). The aIIbb3 integrin also undergoes recy-
cling, in a process that down-regulates platelet aggregation
(20). This event appears to be independent of the b3 cytoplas-
mic domain (21) and probably dependent on the aIIb cytoplas-
mic domain. Thus, it is possible that calcineurin or a cal-
cineurin-like regulatory molecule such as CIB contributes to
recycling. In this regard, Barroso et al. (22) have reported the
cloning of a novel 22-kDa calcium-binding protein (p22) that is
also highly homologous to calcineurin B and required for con-
stitutive membrane traffic. Another protein called CHP, which
is 99% identical to p22, is involved in regulating the Na1/H1
antiporter by interacting with a specific domain of the cytoplas-
mic tail (23). Both of these proteins have two distinct C-termi-
nal EF-hand motifs, like CIB. However, their amino acid se-
quences are only 53% homologous (29% identical) to CIB, but
do suggest the existence of a family of small regulatory Ca21-
binding proteins with two EF-hand motifs.
Both serine/threonine and tyrosine phosphorylation and de-
phosphorylation events appear to play key roles in the regula-
tion of integrin function (24). Recently, it has been shown that
exposure of ligand binding sites on aIIbb3 correlates under some
conditions with phosphorylation of the b3 subunit of aIIbb3
although the extent of b3 phosphorylation is unclear (25, 26). In
addition, a protein kinase that interacts with the b1 and b3
cytoplasmic domains has been identified (27). It is therefore
possible that a protein phosphatase may be directly involved in
integrin regulation. Since CIB shows structural similarity to
calcineurin B, it is conceivable that CIB may also be a subunit
of a multisubunit protein phosphatase. Thus, it will be of in-
terest to determine specific sites that mediate CIB binding to
aIIb, identify other molecules that bind to CIB, and delineate
functional details of this novel Ca21-binding protein.
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